Filing Details
- Accession Number:
- 0000874015-14-000056
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-06-25 19:47:33
- Reporting Period:
- 2014-06-23
- Filing Date:
- 2014-06-25
- Accepted Time:
- 2014-06-25 19:47:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874015 | Isis Pharmaceuticals Inc | ISIS | Pharmaceutical Preparations (2834) | 330336973 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1073387 | Frank C Bennett | C/O Isis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad CA 92010 | Svp, Antisense Research | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-06-23 | 6,200 | $15.38 | 10,536 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-06-23 | 6,200 | $36.97 | 4,336 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2014-06-23 | 5,000 | $15.38 | 9,336 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-06-23 | 5,000 | $36.54 | 4,336 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2014-06-23 | 11,200 | $0.00 | 11,200 | $15.38 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
5,000 | 2009-01-02 | 2015-01-01 | No | 4 | M | Direct |
Footnotes
- Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/15. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 5/22/14.